Companies
Biogen
PharmaceuticalsCambridge, MassachusettsBIIBAbout 7,500 employees
More about Biogen
Biotech company that develops and sells treatments for neurological and rare diseases such as multiple sclerosis, ALS and Alzheimer's
Revenue
$9.9B
Fiscal 2025, up 2.2%
Employees
About 7,500
As of December 2025
Stock
BIIB
Nasdaq
Headquarters
Cambridge, Massachusetts
CEO
Christopher Viehbacher
Since November 2022
BrandsLeqembi (with Eisai), Spinraza, Skyclarys, Zurzuvae, Tecfidera, Vumerity
Current strategyShifting revenue from its older multiple sclerosis drugs to newer products such as Leqembi, Skyclarys and Zurzuvae while cutting costs under its Fit for Growth program
Recent workforce changesFit for Growth program cut a net 1,400 roles by the end of 2025; $165M in restructuring charges in Q2 2026
CompetitorsEisai, Novartis, Roche
Related companiesEli LillyRocheVertex Pharmaceuticals
Checked October 11, 2026 · Sources: sec.gov, sec.gov (2)
Be the first to post about Biogen
No one has started a discussion here yet. Yours is anonymous and appears right away, and we don’t store who wrote it.
Or follow Biogen to see the first post in your watchlist.
Follow Biogen in a feed reader, no account needed: RSS feed